AI Safety Research Neglects Post-Deployment Risks in Healthcare and Finance, SSRC Analysis of 1,178 Papers Finds
What happened
The Social Science Research Council published the Real-World Gaps in AI Governance Research report, analyzing 1,178 AI safety and reliability papers published between January 2020 and March 2025. The study examined research output from major AI developers including Anthropic, Google DeepMind, Meta, Microsoft, and OpenAI, as well as academic institutions such as Carnegie Mellon University, MIT, and Stanford. The report found that safety research across these organizations is heavily concentrated on pre-deployment alignment and evaluation, while post-deployment concerns such as bias are receiving declining attention over time. The analysis also identified significant research gaps in high-risk application domains including healthcare, finance, misinformation, hallucinations, and copyright usage. The findings apply globally and suggest that vendor safety assurances grounded in pre-deployment testing may not adequately address risks that emerge once AI systems operate in live production environments.
Why it matters
- ·Regulatory frameworks in healthcare and financial services increasingly require ongoing lifecycle risk management, meaning organizations that rely solely on vendor pre-deployment safety documentation may face supervisory scrutiny or compliance gaps under existing sector rules.
- ·The documented shift in research attention away from post-deployment bias and performance issues means that enterprise teams deploying AI in production cannot assume vendor safety research reflects real-world operational risks, increasing the operational burden on internal monitoring programs.
- ·The concentration of safety research at the pre-deployment stage creates organizational risk for procurement and vendor management functions, as standard vendor risk assessments and contract terms may not capture deployment-stage failure modes relevant to the organization's specific use case or user population.
Stay ahead of stories like this
Get every Global AI governance development like this one, plus the rest of the week's developments. Every Thursday.
Recent issues
- State-linked attackers and criminal operators are actively weaponizing AI tools as entry points into enterprise systems, turning internal platforms and open-source frameworks into live attack vectors.5 Nov
- Three separate incidents this week each created a new compliance action item: verify your AI vendors' data sourcing, demand agent monitoring coverage guarantees, and audit trusted app identities in your cloud environment.29 Oct
Free every Thursday. Unsubscribe anytime.
Governance controls affected
What to do now
- ☐Establish an independent post-deployment monitoring program that tracks bias, hallucination rates, and performance drift against defined baseline benchmarks on a regular cadence for all AI systems operating in healthcare or financial services contexts.
- ☐Update vendor risk assessment questionnaires to include specific questions about whether the vendor's safety research covers deployment-stage scenarios, diverse user populations, and edge cases relevant to your organization's use case.
- ☐Review existing AI vendor contracts to determine whether audit rights or live operational performance benchmarks are included, and prioritize adding such provisions in renewals or new procurement agreements.
- ☐Classify AI deployments in healthcare and financial services under your risk classification framework and verify that post-deployment validation controls are formally assigned and operationally active for each high-risk system.
- ☐Brief internal compliance and risk committees on the SSRC findings to ensure that pre-deployment evaluation reports from vendors are treated as a starting point rather than a complete risk assessment when approving AI system deployments.
What to watch next
Compliance teams should monitor whether the SSRC findings prompt updated supervisory guidance or rulemaking from sector regulators in healthcare and financial services, particularly from bodies such as the FDA, ONC, CFPB, and prudential banking regulators that have already signaled interest in AI lifecycle risk management. Teams should also track whether the named developers respond publicly to the research gaps identified, as any commitments to expand post-deployment safety research could affect vendor risk profiles. Pending AI governance legislation and regulatory guidance in the European Union, the United Kingdom, and the United States may reference this type of research to justify requirements for continuous monitoring obligations beyond the point of initial deployment.